Home > Oncology > Early MRI breast-cancer screening could benefit women with non-BRCA mutations

Early MRI breast-cancer screening could benefit women with non-BRCA mutations


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Oncology
Reuters Health - 17/02/2022 - For women with non-BRCA1/2 pathogenic variants that confer moderate to high risk for breast cancer, MRI screening starting at age 30 or 35 may substantially reduce breast-cancer mortality, a modeling study suggests. Dr. Kathryn P. Lowry of the University of Washington in Seattle and colleagues used Cancer Intervention and Surveillance Modeling Network simulation models and risk estimates from the Cancer Risk Estimates Related to Susceptibility Consortium to estimate the effects of different screening strategies in U.S. women with ATM, CHEK2, or PALB2 pathogenic variants born in 1985. The mean estimated lifetime breast-cancer risk was 20.9% for women with ATM pathogenic variants, 27.6% for women with CHEK2 pathogenic variants, and 39.5% for women with PALB2 pathogenic variants, the researchers report in JAMA Oncology. Across all the variants, annual mammography alone from ages 40 to 74 was estimated to reduce breast-cancer mortali...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on